Billings Clinic
Especially For:

Clinical Trials

Title   CTSU CALGB 40601: Breast Cancer: HER2-Positive Primary Breast Cancer
Description   A Randomized Phase III Trial of Paclitaxel Combined with Trastuzumab, Lapatinib, or Both as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer.
(Neoadjuvant = prior to surgery.)
IRB Number   CALGB 40601
Category   Breast Cancer
Inclusion/Notes   Stage II or III invasive breast cancer with intent to perform surgical removal after chemotherapy.
Tumors must be HER2 positive, and ER/PR status must be know.

Patient must consent to undergo pre-treatment biopsies. This is in addition to the biopsy done to determine the presence of breast cancer.
Status   Open
Start Date   01/09/2009
Principal Investigator (PI)   Jorge Nieva, MD
Contact Name   Joan Koch, RN
Contact Email   jkoch@billingsclinic.org
Phone   (406) 435-7481
Alternate Phone   (406) 435-7480
Fax   (406) 435-7489
Funding Source   NCI
Print This Page
Email to a Friend
Home | Contact | Site Map | Site Privacy Policy | Terms & Conditions | Patient Privacy Policy | Medical Records | Fast Command
2800 10th Ave. North | P.O. Box 37000 | Billings, Montana 59107 | 406.238.2500
© Copyright 2014 Billings Clinic. All Rights Reserved.